Viromed Medical AG | WebDisclosure

Switch to English

11018	Sociétés
241417	Mots-clés
169938	Articles
129972	Communiqués

Accueil
Sociétés
Viromed Medical AG

COMMUNIQUÉ DE PRESSE

publié le 16/02/2026 à 10:14, il y a 7 mois 1 jour

Viromed Medical AG: Globally unique preclinical data base – Saarland validation as key step toward first physical lung application
Viromed Medical AG presents globally unique preclinical data on cold plasma therapy for lung infections, with Saarland validation confirming a key step towards clinical application

Preclinical Data Viromed Medical AG Cold Plasma Therapy Lung Infections Saarland Validation
BRÈVE

publiée le 27/01/2026 à 16:48, il y a 7 mois 21 jours

MHH dévoilera ses recherches sur la thérapie par plasma froid pour les applications pulmonaires.

Innovation Médicale Résistance Aux Antibiotiques Viromed Medical AG Thérapie Par Plasma Froid Infections Pulmonaires
BRÈVE

publiée le 27/01/2026 à 16:48, il y a 7 mois 21 jours

MHH to Unveil Cold Plasma Therapy Research for Lung Applications

Medical Innovation Antibiotic Resistance Viromed Medical AG Cold Plasma Therapy Lung Infections
COMMUNIQUÉ DE PRESSE

publié le 27/01/2026 à 16:43, il y a 7 mois 21 jours

MHH to Present Scientific Findings on Cold Plasma Therapy for Pulmonary Application at Press Conference in February 2026
MHH to present groundbreaking cold plasma therapy for pulmonary application at press conference in February 2026, addressing urgent clinical need worldwide

Scientific Findings Press Conference Viromed Medical AG Cold Plasma Therapy Pulmonary Application
BRÈVE

publiée le 19/01/2026 à 13:01, il y a 7 mois 29 jours

Viromed Medical AG Achieves Milestone with Ex-Vivo Lung Study

Medical Research Viromed Medical AG Cold Plasma Technology Ex-vivo Lung Study Pharmaceutical Advancement
BRÈVE

publiée le 19/01/2026 à 13:01, il y a 7 mois 29 jours

Viromed Medical AG franchit une étape importante avec une étude pulmonaire ex vivo

Recherche Médicale Viromed Medical AG Technologie Du Plasma Froid Étude Pulmonaire Ex Vivo Progrès Pharmaceutique
COMMUNIQUÉ DE PRESSE

publié le 19/01/2026 à 12:56, il y a 7 mois 29 jours

Correction of a release from 19/01/2026, 11:45 CET/CEST - Viromed Medical AG: Ex-vivo lung study marks milestone for research and approval
Viromed Medical AG to conduct ex-vivo lung study on vital lungs in cooperation with universities for accelerated research and approval processes

Medical Technology Viromed Medical AG Cold Plasma Technology Ex-vivo Lung Study Research Milestone
BRÈVE

publiée le 19/01/2026 à 11:50, il y a 7 mois 29 jours

Viromed Medical AG Advances with Ex-Vivo Lung Study

Viromed Medical AG Cold Plasma Technology Ex-vivo Lung Study Preclinical Research Acceleration Saarland University Collaboration
BRÈVE

publiée le 19/01/2026 à 11:50, il y a 7 mois 29 jours

Viromed Medical AG fait progresser son étude pulmonaire ex vivo

Viromed Medical AG Technologie Du Plasma Froid Étude Pulmonaire Ex Vivo Accélération De La Recherche Préclinique Collaboration De L'Université De La Sarre
COMMUNIQUÉ DE PRESSE

publié le 19/01/2026 à 11:45, il y a 7 mois 29 jours

Viromed Medical AG: Ex-vivo lung study marks milestone for research and approval
Viromed Medical AG's ex-vivo lung study with Saarland University and MHH is a significant milestone for research & approval, accelerating development processes

Research Approval Viromed Medical AG Cold Plasma Technology Ex-vivo Lung Study

Les Echos

Publié le 17/09/2026 à 18:10, il y a 11 heures 28 minutes

Rapport semestriel 2026
Publié le 17/09/2026 à 17:40, il y a 11 heures 58 minutes

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Publié le 17/09/2026 à 17:40, il y a 11 heures 58 minutes

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Publié le 16/09/2026 à 20:46, il y a 1 jour 8 heures

LNA SANTE : 2026 First Half Results
Publié le 16/09/2026 à 18:45, il y a 1 jour 10 heures

STEF : Droits de vote au 31 08 2026

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 18/09/2026 à 04:25, il y a 1 heure 13 minutes

Empress Announces Resumption of Trading
Publié le 18/09/2026 à 00:55, il y a 4 heures 43 minutes

Tectonic Metals Announces Results of the 2026 Annual General Meeting
Publié le 18/09/2026 à 00:25, il y a 5 heures 13 minutes

CoTec Holdings Corp. Announces Initial Closing of Private Placement of Unsecured Convertible Debentures
Publié le 17/09/2026 à 22:15, il y a 7 heures 23 minutes

Rocky Shore Gold Announces Non-Brokered Private Placement
Publié le 17/09/2026 à 22:15, il y a 7 heures 23 minutes

Vanta Attends 2026 All-In Summit in Los Angeles, a Leading Gathering of Business, Investment and Industry Leaders

Voir tout ACCESSWIRE

EQS Group

Publié le 17/09/2026 à 19:00, il y a 10 heures 37 minutes

Max Verstappen Passes All 100 Karts in 14 Laps in Red Bull's Max vs 100
Publié le 17/09/2026 à 18:58, il y a 10 heures 39 minutes

EQS-Adhoc: H2APEX Group SCA: General Partner of H2APEX Group SCA resolves to prepare for the transfer of its stock exchange listing from the Regulated Market (Prime Standard) to the Scale segment of the Frankfur
Publié le 17/09/2026 à 18:25, il y a 11 heures 12 minutes

Magentic raises $18M to build the AI workforce for the physical world
Publié le 17/09/2026 à 18:10, il y a 11 heures 27 minutes

A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%
Publié le 17/09/2026 à 17:46, il y a 11 heures 51 minutes

RBI categorically denies the allegations of short-seller report